Is RYTM a good stock to buy? We came across a bearish thesis on Rhythm Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bears’ thesis on RYTM. Rhythm Pharmaceuticals, Inc.’s share was trading at $87.72 as of April 20th.
Pressmaster/Shutterstock.com
Rhythm Pharmaceuticals (RYTM) is a rare-disease biotech built almost entirely around setmelanotide, an MC4R agonist targeting genetic and hypothalamic obesity, but its concentrated strategy...
